These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 16497299)
41. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Lubelski J; Konings WN; Driessen AJ Microbiol Mol Biol Rev; 2007 Sep; 71(3):463-76. PubMed ID: 17804667 [TBL] [Abstract][Full Text] [Related]
42. Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells. Stavrovskaya AA; Rybalkina EY Biochemistry (Mosc); 2018 Jul; 83(7):779-786. PubMed ID: 30200862 [TBL] [Abstract][Full Text] [Related]
43. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Hait WN; Yang JM Semin Oncol; 2005 Dec; 32(6 Suppl 7):S16-21. PubMed ID: 16360718 [TBL] [Abstract][Full Text] [Related]
44. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Joyce H; McCann A; Clynes M; Larkin A Expert Opin Drug Metab Toxicol; 2015 May; 11(5):795-809. PubMed ID: 25836015 [TBL] [Abstract][Full Text] [Related]
45. In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network. Kolaczkowski M; Kolaczowska A; Luczynski J; Witek S; Goffeau A Microb Drug Resist; 1998; 4(3):143-58. PubMed ID: 9818966 [TBL] [Abstract][Full Text] [Related]
46. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Orina JN; Calcagno AM; Wu CP; Varma S; Shih J; Lin M; Eichler G; Weinstein JN; Pommier Y; Ambudkar SV; Gottesman MM; Gillet JP Mol Cancer Ther; 2009 Jul; 8(7):2057-66. PubMed ID: 19584229 [TBL] [Abstract][Full Text] [Related]
47. [Influence of ABC-transporters on intracellular distribution of anticancer drugs and contribution of this index to multidrug resistance phenotype]. Ravcheeva AB; Bogush EA; Bogush TA Antibiot Khimioter; 2005; 50(2-3):22-9. PubMed ID: 16308936 [TBL] [Abstract][Full Text] [Related]
48. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. Sosnik A Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1828-51. PubMed ID: 24055628 [TBL] [Abstract][Full Text] [Related]
49. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Assaraf YG Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765 [TBL] [Abstract][Full Text] [Related]
50. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review. Liu FS Taiwan J Obstet Gynecol; 2009 Sep; 48(3):239-44. PubMed ID: 19797012 [TBL] [Abstract][Full Text] [Related]
51. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Modok S; Mellor HR; Callaghan R Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355 [TBL] [Abstract][Full Text] [Related]
52. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160 [TBL] [Abstract][Full Text] [Related]
53. Multidrug resistance in cancer: role of ATP-dependent transporters. Gottesman MM; Fojo T; Bates SE Nat Rev Cancer; 2002 Jan; 2(1):48-58. PubMed ID: 11902585 [TBL] [Abstract][Full Text] [Related]
54. Curcumin as chemosensitizer. Limtrakul P Adv Exp Med Biol; 2007; 595():269-300. PubMed ID: 17569216 [TBL] [Abstract][Full Text] [Related]
55. Search for specific inhibitors of multidrug resistance in cancer. Sarkadi B; Müller M Semin Cancer Biol; 1997 Jun; 8(3):171-82. PubMed ID: 9465371 [TBL] [Abstract][Full Text] [Related]
56. [Multidrug resistance of cancer cells mediated by ABC superfamily transporters]. Ueda K Nihon Rinsho; 1997 May; 55(5):1024-9. PubMed ID: 9155147 [TBL] [Abstract][Full Text] [Related]
57. Non-P-glycoprotein drug export mechanisms of multidrug resistance. List AF Semin Hematol; 1997 Oct; 34(4 Suppl 5):20-4. PubMed ID: 9408957 [TBL] [Abstract][Full Text] [Related]
58. Immunosuppressors and reversion of multidrug-resistance. Aouali N; Eddabra L; Macadré J; Morjani H Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826 [TBL] [Abstract][Full Text] [Related]
59. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427 [TBL] [Abstract][Full Text] [Related]
60. Overcoming multidrug-resistance in cancer: statins offer a logical candidate. Mehta NG; Mehta M Med Hypotheses; 2010 Feb; 74(2):237-9. PubMed ID: 19879695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]